• 1
    National Institute for Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal. London, UK: NICE, 2004.
  • 2
    Guidelines for Economic Evaluation of Pharamaceuticals: Canada (2nd ed.). Ottawa: The Canadian Coordinating Office for Health Technology Assessment, 1997.
  • 3
    Feeny D, Furlong W, Torrance GW, et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care 2002;40:11328.
  • 4
    Torrance GW, Feeny DH, Furlong WJ, et al. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care 1996;34:70222.
  • 5
    The EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199208.
  • 6
    Austin PC. A comparison of methods for analyzing health-related quality-of-life measures. Value Health 2002;5:32937.
  • 7
    Austin PC, Escobar M, Kopec JA. The use of the Tobit model for analyzing measures of health status. Qual Life Res 2000;9:90110.
  • 8
    Huang IC, Frangakis C, Atkinson MJ, et al. Addressing ceiling effects in health status measures: a comparison of techniques applied to measures for people with HIV disease. Health Serv Res 2008;43(1 Pt 1):32739.
  • 9
    Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. Oxford: Oxford University Press, 1996.
  • 10
    Ware JE, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME. Users' Manual for the SF-36v2 Health Survey (2nd ed.). Lincoln: Quality Metric, 2007.
  • 11
    Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:183340.
  • 12
    Grootendorst P. Censoring in statistical models of health status: What happens when one can do better than “1”. Qual Life Res 2000;9:91114.
  • 13
    Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000;320:1197200.
  • 14
    Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med 2000;19:114164.
  • 15
    Walters SJ, Campbell MJ. The use of bootstrap methods for analysing health-related quality of life outcomes (particularly the SF-36). Health Qual Life Outcomes 2004;2:70.
  • 16
    Long JS, Ervin LH. Using heteroscedasticity consistent standard errors in the linear regression model. Am Stat 2000;54:21724.
  • 17
    Dempster AP, Laird NM, Rubin DB. Maximum Likelihood from Incomplete Data via the EM Algorithm. J R Stat Soc Series B Stat Methodol 1977;39:138.
  • 18
    Sullivan PW, Ghushchyan V. Preference-based EQ5D index scores for chronic conditions in the United States. Med Decis Making 2006;26:41020.